Evidence map›Paper›PMID 42432499›Full record

ArticleBMC immunology2026

Cetuximab combination with cytokine induced killer cells effectively inhibit conjunctival squamous cell carcinoma in vitro.

Hossein Aghaei, Mehdi Khakpour, Samaneh Dehghan, Ali Ghamari, Alireza Shoae-Hassani

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hossein AghaeiEye Research Center, The Five Senses Institute, Iran University of Medical Sciences, Tehran, Iran.
Mehdi KhakpourDepartment of Ophthalmology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Samaneh DehghanEye Research Center, The Five Senses Institute, Iran University of Medical Sciences, Tehran, Iran.
Ali GhamariDepartment of Neurosurgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Alireza Shoae-HassaniEye Research Center, The Five Senses Institute, Iran University of Medical Sciences, Tehran, Iran. cell.therapy@yahoo.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We explored the potential effects of the anti-EGFR monoclonal antibody Cetuximab when combined with activated cytokine-induced killer cells (CIKs) as a novel treatment strategy for human conjunctival squamous cell carcinoma (CSCCs) in vitro. The CSCC used in our study was obtained from an explant of a patient diagnosed with the condition. After molecular and pathological confirmations, the CSCC was established as proliferating and confluent cultures and was exposed continuously for seven days to different concentrations of Cetuximab (10

Indexed as

Antineoplastic Agents, ImmunologicalCarcinoma, Squamous CellCetuximabConjunctival NeoplasmsCytokine-Induced Killer CellsCell ProliferationCytotoxicity, ImmunologicErbB ReceptorsHumansLimbal Stem CellsAntineoplastic Agents, ImmunologicalCetuximabErbB ReceptorsAnti EGFRCIKCSCCImmune Cell TherapyLimbal Stem CellOcular carcinoma

Identifiers

PMID42432499
PMCPMC13660011

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.